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OBJECTIVE
Adults with diabetes typically take multiple medications for hyperglycemia,
diabetes-associated conditions, and other comorbidities. Medication adherence
is associated with improved outcomes, including reduced health care costs, hos-
pitalization, and mortality. We conducted a retrospective analysis of a large phar-
macy claims database to examine patient, medication, and prescriber factors
associated with adherence to antidiabetic medications.
RESEARCH DESIGN AND METHODS
We extracted data on a cohort of >200,000 patients who were treated for diabe-
tes with noninsulin medications in the second half of 2010 and had continuous
prescription benefits eligibility through 2011. Adherence was defined as a medi-
cation possession ratio ‡0.8. We used a modified adherence measure that
accounted for switching therapies. Logistic regression analysis was performed
to determine factors independently associated with adherence.
RESULTS
Sixty-nine percent of patients were adherent. Adherence was independently asso-
ciated with older age, male sex, higher education, higher income, use of mail order
versus retail pharmacies, primary care versus nonendocrinology specialist prescrib-
ers, higher daily total pill burden, and lower out-of-pocket costs. Patients who were
new to diabetes therapy were significantly less likely to be adherent.
CONCLUSIONS
Several demographic, clinical, and potentially modifiable system-level factors
were associated with adherence to antidiabetic medications. Patients typically
perceived to be healthy (those who are younger, new to diabetes, and on few
other medications) may be at risk for nonadherence. For all patients, efforts to
reduce out-of-pocket costs and encourage use of mail order pharmacies may
result in higher adherence.
Adults with type 2 diabetes are often prescribed multiple medications to treat
hyperglycemia, diabetes-associated conditions such as hypertension and dyslipide-
mia, and other comorbidities. Medication adherence is an important determinant of
outcomes in patients with chronic diseases. For those with diabetes, adherence to
medications is associated with better control of intermediate risk factors (1–4),
lower odds of hospitalization (3,5–7), lower health care costs (5,7–9), and lower
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mortality (3,7). Estimates of rates of ad-
herence to diabetes medications vary
widely depending on the population
studied and how adherence is defined.
One review found that adherence to
oral antidiabetic agents ranged from
36 to 93% across studies and that adher-
ence to insulin was ;63% (10).
Although much is known about the ad-
verse “downstream” effects of medica-
tion nonadherence, the determinants of
medication adherence are less well de-
fined. Most studies have looked at either
individual-level or system-level factors in-
dependently, whereas few studies have
used large generalizable cohorts. Using a
large pharmacy claims database, we as-
sessed determinants of adherence to oral
antidiabetic medications in.200,000 U.S.
adults with type 2 diabetes. We looked
at a wide range of variables and catego-
rized those potential determinants into
patient factors, prescriber factors, and
factors related to the prescribed medica-
tion or the prescription system.
RESEARCH DESIGN AND METHODS
Data Sources
Data were extracted from the infor-
mation warehouse of Medco Health
Solutions, a large U.S. managed-care
company that provided pharmacy man-
agement services to a range of clients,
including employers and health plans.
(Medco Health Solutions merged with
another large pharmacy benefit man-
agement company, Express Scripts, in
April 2012.) The information warehouse
is a data repository that includes demo-
graphic, eligibility, and pharmacy claims
information related to the dispensing
event. The sample includes patients
from all 50 states and the larger U.S.
territories including Puerto Rico, the Vir-
gin Islands, and Guam. Fifty-three per-
cent of the patients received their
pharmacy benefits from a health plan,
17% labor and government, 19% large
employer groups, 2% Medicare, and
9% small business groups and others.
Using prescription claims from the da-
tabase, we extracted drug utilization
data and determined study eligibility.
Eligibility was based on drug type, ben-
efits, and prescription history. We
selected a cohort of members treated
for diabetes with noninsulin medica-
tions (oral agents or GLP-1 agonists) in
the second half of 2010 who had con-
tinuous prescription benefits eligibility
through 2011. Each patient was fol-
lowed for 12 months from their index
diabetes claim date identified during
the 6-month targeting period. From
each patient’s prescription history, we
collected the date the prescription was
filled, how many days the supply would
last, the National Drug Code number,
and the drug name. For patients in-
cluded in the analysis, household in-
come and education level were provided
by a commercial vendor and appended
to the file.
Given the difficulty in assessing insu-
lin adherence with measures such as
medication possession ratio (MPR), we
excluded patients using insulin when
defining the cohort. To simplify the anal-
yses with respect to distinguishing med-
ication switches and additions, we also
restricted the analysis to patients using
no more than two antidiabetic medica-
tions during the targeting period. This
decision had minimal impact on sample
size, with ,3.5% of patients being on
three or more medications for diabetes.
Predictors and Outcomes of Interest
Predictor variables were defined a priori
and grouped into three categories: 1) pa-
tient factors including age, sex, education,
income, region, past exposure to therapy
(new to diabetes therapy vs. continuing
therapy), and concurrent chronic condi-
tions; 2) prescription factors including re-
fill channel (retail vs. mail order), total pill
burden per day, and out of pocket costs;
and 3) prescriber factors including age,
sex, and specialty. Pill burdenwas defined
for all oral maintenance medications (di-
abetes and nondiabetes) filled and was
computed by multiplying the average
number of maintenance medications
per month by the average number of
oral maintenance pills per day, which
was then converted to a 30-day period.
Patient out-of-pocket prescription costs
per month were estimated by summing
the total copays and deductibles for each
chronic maintenance prescription, divid-
ing by the number of days supply (result-
ing in the cost per day), and then
multiplying by 30 to reflect a 30-day pe-
riod. Patients filling one or more of their
diabetes medications by mail were con-
sidered mail channel.
Our primary outcome of interest was
adherence to noninsulin antidiabetic
medications. To assess adherence, we
calculated an MPR for each patient.
The ratio captures how often patients
refill their medications and is a standard
metric that is consistent with the Na-
tional Quality Forum’s measure of ad-
herence to medications for chronic
conditions. MPR was defined as the
proportion of days a patient had a sup-
ply of medication during a calendar
year or equivalent period. We consid-
ered patients to be adherent if their
MPR was 0.8 or higher, implying that
they had their medication supplies for
at least 80% of the days. An MPR of 0.8
or above is a well-recognized index of
adherence (11,12). Studies have sug-
gested that patients with chronic dis-
eases need to achieve at least 80%
adherence to derive the full benefits
of their medications (13).
After establishing a patient’s adherence
status, we then determined whether a pa-
tient was persistent, that is whether they
had not discontinued or had at least a 45-
day gap in their targeted therapy. We
used a modified adherence measure,
which was meant to account for changing
diabetes drug classes, in this analysis. For
the modified measure, patients with an
MPR,0.80 were reclassified as adherent
if they were persistent (,45-day gap) and
subsequently filled a diabetes therapy (in-
cluding insulin) different than their index
regimen.
Patients on two diabetes agents were
credited for days with either medica-
tion. This method conservatively avoids
misclassifying patients who may have
switched from one class to another,
which can happen when averaging
MPRs for each class. Of the 218,384 di-
abetic patients, 59,035 (27.0%) were
taking more than one medication to
treat their diabetes and, using this
methodology, were considered adher-
ent to their diabetes therapy. Of these
patients, 2,706 (4.5% of those on dual
therapy considered adherent by our
methodology; 1.2% of the total popula-
tion) had an MPR ,0.8 for at least one
of their medications; thus, their overall
adherence could be overestimated.
Analyses
We used a logistic regression analysis to
examine the independent effects of pa-
tient, medication, and prescriber vari-
ables on diabetes medication adherence.
For the logistic model, we used a stepwise
regression, with variables selection for
entry equal to univariate P of 0.05 or
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less. The C-statistic, an indicator for
model fit, was 0.73, suggesting reason-
able fit. The number of chronic disease
conditions and patient total pill burden
were highly positively correlated, and
thus only patient pill burden was consid-
ered in themultivariate analysis. Missing
values for a given variable were assigned
the value of the mode.
We considered findings to be statisti-
cally significant if the P value for the
relationship was ,0.05. Precision of es-
timates was assessed by 95% CIs. All sta-
tistical analyses were performed using
SAS software version 9.3 (14).
RESULTS
There were 218,384 patients who met
the criteria for inclusion. Table 1
describes the analyzed population.
Sixty-nine percent met the criteria for
adherence using the modified defini-
tion. Over 51% were Medicare eligible
(age $65 years), 53% were female,
35% had a college or postgraduate edu-
cation, and 26% had estimated annual
household income ,$30,000. Sixty-
one percent usually filled their prescrip-
tions at retail pharmacies. Forty-one
percent resided in the South geographic
region and 25% in the Midwest. There
were 17% of patients considered new to
diabetes therapy. Patients in the study
also filled prescriptions for a number of
comorbid conditions: .80% filled pre-
scriptions commonly used to treat hy-
pertension, 67% filled prescriptions for
medications to treat high cholesterol,
and 25% filled prescriptions commonly
used to treat chronic gastrointestinal
disorders. Only 17% were treated by
specialists and 4% by endocrinologists.
Patient Factors
Results of the multivariate analysis are
presented in Table 2. Previous exposure
to diabetes therapy had a significant im-
pact on adherence. Patients new to ther-
apywere 61% less likely to be adherent to
their diabetes medication. There was
also a clear age effect. Patients 25–44
years of age were 49% less likely to be
adherent when compared with patients
45–64 years of age. Patients aged 65–74
years were 27% more likely to be adher-
ent, and those aged 75 years and above
were 41% more likely to be adherent
when compared with the 45–64 year
age-group. Men were significantly more
likely to be adherent than women.
Table 1—Characteristics of the study population by adherence status
Adherent Nonadherent Total
Patient factors
Total patients, n (%) 151,010 (69.1) 67,374 (30.9) 218,384 100%
Patient exposure to diabetes
therapy, n (%)
New to therapy 17,486 (11.6) 20,067 (29.8) 37,553 (17.2)
Continuing therapy 133,524 (88.4) 47,307 (70.3) 180,831 (82.8)
Patient age (years)
Mean (SD) 66.4 (13.4) 61.6 (15.50) 64.9 (4.8)
Median 67.0 62.0 66.0
Patient age-group (years), n (%)
20–44 7,113 (4.7) 8,793 (13.0) 15,906 (7.3)
45–64 60,711 (40.2) 30,157 (44.8) 90,868 (41.6)
65–74 41,827 (27.7) 14,906 (22.1) 56,733 (26.0)
75+ 41,359 (27.4) 13,518 (20.1) 54,877 (25.1)
Patient sex, n (%)
Male 72,605 (48.1) 29,922 (44.4) 102,527 (47.0)
Female 78,362 (51.9) 37,430 (55.6) 115,792 (53.0)
Missing 43 (0.0) 22 (0.0) 65 (0.0)
Patient education, n (%)
Completed high school 94,683 (62.7) 45,081 (66.9) 139,764 (64.0)
Completed college 39,327 (26.0) 16,052 (23.8) 55,379 (25.4)
Completed graduate school 16,237 (10.8) 5,866 (8.7) 22,103 (10.1)
Attended vocational/
technical 763 (0.5) 375 (0.6) 1,138 (0.5)
Patient income, n (%)
,$30,000 41,059 (27.2) 16,566 (24.6) 57,625 (26.4)
$$30,000 to $59,999 60,374 (40.0) 30,244 (44.9) 90,598 (41.5)
$$60,000 49,577 (32.8) 20,584 (30.6) 70,161 (32.1)
Patient geographic region, n (%)
Northeast 33,404 (22.1) 14,747 (21.9) 48,151 (22.0)
Midwest 38,080 (25.2) 15,497 (23.0) 53,577 (24.5)
West 18,263 (12.1) 8,359 (12.4) 26,622 (12.2)
South 61,263 (40.6) 28,771 (42.7) 90,034 (41.2)
Treated chronic disease
conditions, n (%)
Gastrointestinal 38,722 (25.3) 14,235 (22.3) 52,957 (25.1)
High cholesterol 105,336 (71.7) 36,470 (57.0) 141,806 (67.2)
Hypertension 123,563 (84.1) 47,030 (73.5) 170,593 (80.9)
Obesity 259 (0.2) 234 (0.4) 493 (0.2)
Peripheral vascular disease 4,359 (3.0) 1,640 (2.6) 5,999 (2.8)
Renal 541 (0.4) 380 (0.6) 921 (0.4)
Depression 24,826 (16.4) 10,614 (15.8) 35,440 (16.2)
Prescription factors
Drug channel, n (%)
Mail 62,957 (41.7) 22,025 (32.7) 84,982 (38.9)
Retail 88,053 (58.3) 45,359 (67.3) 133,492 (61.1)
Pill burden and cost, n (%)
Total pill burden per day,
mean (SD) 5.2 (3.0) 4.1 (2.5) 4.9 (2.9)
Out of pocket cost ($)/month,
mean (SD) 44.68 (48.69) 69.41 (74.95) 52.31 (59.97)
Prescriber factors
Prescriber specialty, n (%)
Endocrinologist 5,494 (3.6) 2,681 (4.0) 8,175 (3.7)
Primary care 125,404 (83.0) 54,003 (80.1) 158,815 (82.2)
Other specialist 20,112 (13.3) 10,690 (15.9) 30,802 (14.1)
Prescriber age, n (%)
Mean (SD) 52.9 (9.5) 52.4 (9.5) 52.7 (9.5)
Median 55.0 55.0 55.0
Prescriber sex, n (%)
Female 30,863 (20.4) 15,314 (22.7) 46,177 (21.15)
Male 120,147 (79.6) 52,060 (77.3) 172,207 (78.86)
606 Adherence to Diabetes Medications Diabetes Care Volume 38, April 2015
Education level and household income
were both associated with adherence.
The higher the estimated academic
achievement, the more likely the patient
was to be adherent. Patients completing
graduate school were 41% more likely to
be adherent when compared with pa-
tients with a high school equivalent ed-
ucation. Patients with an annual income
.$60,000 were also more likely to be
adherent when compared with patients
with a household income,$30,000. There
was little variation across geographic re-
gions, although patients living in the Mid-
west were 12%more likely to be adherent
than patients in the West.
Prescription Factors
The largest effect size was observed for
patients obtaining their prescription anti-
diabetic medications by mail. Patients us-
ing the mail channel were more than
twice as likely to be adherent to their
antidiabetic medications when compared
with patients filling their prescriptions at
retail pharmacies. Total daily pill burden
was positively associated with antidia-
betic medication adherence. For each
additional pill a patient took per day,
adherence to antidiabetic medications
increased by 22%. Patient out-of-pocket
costs were negatively associated with
adherence. For each additional $15 in
out-of-pocket costs per month, diabetes
medication adherence decreased by 11%.
Prescriber Factors
We found fewmeaningful differences in
patient adherence according to pre-
scriber factors. There were no differ-
ences in patient adherence by sex of the
prescriber. Although there was a statisti-
cally significant association of adherence
with prescriber age, the effect size was
very small (for each additional year of
prescriber age, the odds of adherence in-
creased by 0.2%). There was no differ-
ence in adherence between those with
primary care and endocrinologist pre-
scribers, although the proportion of the
latter was low. Patients with nonendocri-
nologist specialist prescribers showed
slightly but significantly lower adherence
than those with primary care prescribers.
CONCLUSIONS
We found that several patient demo-
graphic and clinical factors were associ-
ated with higher adherence to noninsulin
antidiabetic medications: older age, male
sex, higher education level, higher in-
come, and presence of comorbid chronic
conditions. Being new to diabetes ther-
apy was associated with lower adher-
ence. Prescription and “system” factors
associatedwith higher odds of adherence
included using a mail order channel ver-
sus retail pharmacies and having a higher
total daily pill burden. Higher total out-of-
pocket costs were associated with lower
odds of adherence. Specialtywas the only
prescriber factor that was independently
associated with adherence; compared
with patients of primary care prescrib-
ers, patients of nonendocrinology spe-
cialist prescribers had slightly lower
odds of adherence.
Prior studies on the effects of age on
adherence have provided contradictory
results. Older patients had higher adher-
ence to medications for any of eight
chronic conditions, including diabetes
(15), and specifically for their first pre-
scription for an oral antidiabetic medi-
cation (16). However, an analysis of
adherence to guideline-based medica-
tion use for patients with cardiovascular
disease found that younger patients
were more likely to be adherent (17).
Lower rates of medication adherence
in women have been reported for statin
use (18) and in studies looking at medi-
cations for a variety of chronic condi-
tions, including diabetes (15,19).
Although polypharmacy is an impor-
tant risk factor for medication interac-
tions and adverse events, our analyses
suggest that it is associated with higher,
rather than lower, odds of adherence to
antidiabetic medications. This association
was also noted in a large study of adher-
ence to medications for one of eight
chronic conditions, including diabetes
(15). However, another study examining
medications for control of blood glucose,
blood pressure, and cholesterol found
that a higher total number of prescribed
medications was not associated with
adherence to diabetes and cholesterol
medications and was associated with
lower adherence to blood pressure
medications (20).
In our study, characteristics that
suggest a “healthier” patient (being
younger, new to diabetes therapy, and
taking few other medications) were all
associated with lower odds of adher-
ence to antidiabetic medications. This
suggests that acceptance of a chronic
illness diagnosis and the potential
Table 2—Odds ratios, 95% CI, and P values for multivariate model of factors
associated with diabetes medication adherence
Odds ratio 95% CI P
Patient factors
Patient exposure to diabetes therapy
New to therapy vs. continuing therapy 0.39 0.38, 0.40 ,0.0001
Patient age-group (years)
25–44 vs. 45–64 0.51 0.49, 0.53 ,0.0001
65–74 vs. 45–64 1.27 1.23, 1.30 ,0.0001
.75 vs. 45–64 1.41 1.37, 1.44 ,0.0001
Patient sex
Male vs. female 1.14 1.12, 1.16 ,0.0001
Patient education
Vocational vs. high school equivalent 1.06 0.92, 1.22 0.4105
College grad vs. high school equivalent 1.20 1.17, 1.23 ,0.0001
Graduate school vs. high school equivalent 1.41 1.36, 1.46 ,0.0001
Patient income
$30k to $60k vs. ,$30k 0.93 0.91, 0.95 ,0.0001
.$60k vs. ,$30k 1.27 1.23, 1.30 ,0.0001
Patient geographic region
Midwest vs. West 1.12 1.08, 1.16 ,0.0001
Northeast vs. West 1.04 1.00, 1.08 0.0448
South vs. West 1.00 0.97, 1.03 0.9475
Prescription factors
Prescription drug channel: mail vs. retail 2.09 2.04, 2.13 ,0.0001
Total pill burden 1.22 1.21, 1.22 ,0.0001
Out-of-pocket costs (30 days) 0.89 0.89, 0.89 ,0.0001
Prescriber factors
Specialty: endocrinologist vs. primary care 1.01 0.96, 1.07 0.6076
Specialty: other specialist vs. primary care 0.91 0.89, 0.94 ,0.0001
Prescriber age 1.002 1.002, 1.003 0.004
care.diabetesjournals.org Kirkman and Associates 607
consequences may be an important, but
perhaps overlooked, determinant of
medication-taking behavior.
Our findings that use of mail order
channels is associated with adherence
supports the results of other studies on
medication adherence (21–25). A recent
analysis of refill claims byMedicare Part D
beneficiaries also showed increased ad-
herence to medications for diabetes, hy-
pertension, or high cholesterol in those
using mail order channels. Use of this
channel was strongly associated with
past adherence (suggesting that those
more likely to adhere are more likely
to select mail order channels) but was
still significantly associated with current
adherence when controlled for past
adherence (25).
Our findings regarding income and
costs are important reminders that pre-
scribers should consider the impact of
medication costs on patients with diabe-
tes. Out-of-pocket costs are an impor-
tant determinant of adherence to
statins (26) and a self-reported cause of
underuse of medications in one in seven
insured patients with diabetes (27).
Lower income has previously been
shown to be associated with poor adher-
ence to diabetes medications (15) and a
self-reported cause of cost-related med-
ication underuse (27).
Most provider factors that could be
assessed in the database (provider age,
sex, and geographic location) were not
associated with medication adherence.
Patients of endocrinologist prescribers
exhibited no higher odds of adherence
than patients of primary care prescrib-
ers, although the proportion of patients
receiving prescriptions from endocrinol-
ogists was small. Patients of nonendo-
crinologist specialist prescribers exhibited
lower odds of adherence than patients
of primary care prescribers. These re-
sults may support other groups’ findings
that continuity of care (28) is associated
with medication adherence and health
outcomes in patients with diabetes.
There are several strengths to our
study. The claims database includes a
very large cohort of patients from
throughout the U.S. who are cared for
in diverse health systems and covered
by numerous types of pharmacy benefits,
which may make our results more gener-
alizable than analyses performed in
closed systems. The database includes
numerous variables related to patient
demographics, patient comorbidities,
provider demographics and specialty,
and “system” factors such as prescription
refill channel and out-of-pocket costs.
Our study also has several limitations.
Race/ethnicity data were not available in
the database used for this study. Future
studies should aim to better understand
potential racial and ethnic disparities in
adherence and ways to ameliorate them.
Because of the methodology, we were
also not able to account for primary non-
adherence (not filling an initial prescrip-
tion for a medication), which may be an
even greater problem than lack of persis-
tencewith ongoing therapy (29). Addition-
ally, although MPR is a well-accepted
measure of medication adherence, it
measures only refill behavior and not ac-
tual medication taking.
As is often done in research analyses,
we dichotomized adherence based on a
threshold for refill behavior, whereas
adherence clearly falls on a continuum.
We were unable to assess adherence
to insulin therapy, as there are inherent
difficulties imputing adherence from
medication possession ratio for insulin
(insulin doses may vary from day to
day, prescribed volumes are fixed, and
there may be wastage due to priming
of devices and expiration of the medi-
cations). Although we were able to as-
certain common comorbidities from
prescription claims algorithms, we
were not specifically able to account
for the presence of chronic complica-
tions of diabetes, which may be associ-
ated with adherence. In addition, we
did not have clinical data such as hemo-
globin A1c results.
Because of the complexity of the anal-
yses, we only assessed adherence in pa-
tients who were prescribed one or two
noninsulin antidiabetic medications, not
in those prescribed three or more. How-
ever, patients in the latter category
made up ,3.5% of the total cohort.
We used a modified measure of adher-
ence to account for changing classes of
antidiabetic medications, presumably
due to side effects or lack of efficacy,
which may be common in type 2 diabe-
tes. However, our results were not dif-
ferent when these patients (5% of the
total cohort) were instead considered to
be nonadherent. As is the case with all
large database analyses, our results are
hypothesis generating and cannot prove
cause and effect.
Our findings should not be used to
strictly define the “nonadherent” pa-
tient. Most of the factors associated
with adherence had small independent
effect sizes, and there is certainly no
“type” of adherent, or nonadherent, pa-
tient. Rather, our results suggest that
health care providers should consider
many factors beyond common wisdom
when addressing the issue of medica-
tion adherence. They should not assume
that patients who seem uncomplicated
(young, newly diagnosed with type 2 di-
abetes, without substantial comorbid-
ities) are free of barriers to medication
adherence. In fact, they may need more
support to help them overcome barriers
to adherence, one of which may be ac-
cepting the reality of having a chronic
illness. Even nonmodifiable variables
can increase awareness of the common
issue of nonadherence and potentially
drive adherence-promoting interven-
tions. Whenever possible, providers
and payers should work together to ad-
dress potentially modifiable factors as-
sociated with lower likelihood of
adherence, such as minimizing out-of-
pocket costs and encouraging the use
of mail order channels.
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16. Guénette L, Moisan J, Breton M-C, Sirois C,
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